2-(4-(2-carboxyethyl)phenethylamino)-5--n-ethylcarboxamidoadenosine and Skin-Diseases

2-(4-(2-carboxyethyl)phenethylamino)-5--n-ethylcarboxamidoadenosine has been researched along with Skin-Diseases* in 2 studies

Other Studies

2 other study(ies) available for 2-(4-(2-carboxyethyl)phenethylamino)-5--n-ethylcarboxamidoadenosine and Skin-Diseases

ArticleYear
Topical application of the adenosine A2A receptor agonist CGS-21680 prevents phorbol-induced epidermal hyperplasia and inflammation in mice.
    Experimental dermatology, 2014, Volume: 23, Issue:8

    The nucleoside adenosine is a known regulator of immunity and inflammation that mediates, at least in part, the anti-inflammatory effect of methotrexate, an immunosuppressive agent widely used to treat autoimmune inflammatory diseases. Adenosine A2A receptors play a key role in the inhibition of the inflammatory process besides promoting wound healing. Therefore, we aimed to determine the topical effect of a selective agonist, CGS-21680, on a murine model of skin hyperplasia with a marked inflammatory component. Pretreatment with either CGS-21680 (5 μg per site) or the reference agent dexamethasone (200 μg/site) prevented the epidermal hyperplasia and inflammatory response induced by topical application of 12-O-tetradecanoylphorbol-13-acetate (TPA, 2 nmol/site) for three consecutive days. The histological analysis showed that both CGS-21680 and dexamethasone produced a marked reduction of inflammatory cell infiltrate, which correlated with diminished myeloperoxidase (MPO) activity in skin homogenates. Both treatments reduced the levels of the chemotactic mediators LTB4 and CXCL-1, and the inflammatory cytokine TNF-α, through the suppression of NFκB phosphorylation. The immunohistochemical analysis of the hyperproliferative markers cytokeratin 6 (CK6) and Ki67 revealed that while both agents inhibit the number of proliferating cells in the epidermis, CGS-21680 treatment promoted dermal fibroblasts proliferation. Consistently, increased collagen deposition in dermis was observed in tissue sections from agonist-treated mice. Our results showed that CGS 21680 efficiently prevents phorbol-induced epidermal hyperplasia and inflammation in mice without the deleterious atrophic effect of topical corticosteroids.

    Topics: Adenosine; Adenosine A2 Receptor Agonists; Administration, Topical; Animals; Anti-Inflammatory Agents; Cell Proliferation; Collagen; Cytokines; Dexamethasone; Disease Models, Animal; Epidermis; Female; Hyperplasia; Inflammation; Mice; Peroxidase; Phenethylamines; Skin Diseases; Tetradecanoylphorbol Acetate

2014
Targeting adenosine receptors to prevent inflammatory skin diseases.
    Experimental dermatology, 2014, Volume: 23, Issue:8

    Adenosine mediates its effects through activation of a family of four G-protein-coupled receptors, named A1 , A2A , A2B and A3 . This nucleoside plays an important role in immunity and inflammation, and the A2A adenosine receptor subtype has a key role in the inhibition of inflammatory processes besides promoting wound healing. In this issue of Experimental Dermatology, Arasa et al. show that the topical application of a selective A2A agonist, CGS 21680, to mouse skin reduced epidermal hyperplasia as well as skin inflammation, similarly to topical corticoids, without side effects like skin atrophy. Rigorously following up this work is important for the development of novel treatment strategies for chronic hyperproliferative inflammatory dermatoses, such as targeting the A2A adenosine receptor family.

    Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Epidermis; Female; Inflammation; Phenethylamines; Skin Diseases

2014